Ultrasound-sensitive nanodroplets achieve targeted neuromodulation.
Authors: Lea-Banks H, Meng Y, Wu SK, Belhadjhamida R, Hamani C, Hynynen K
Focused ultrasound (FUS) offers an attractive tool for non-invasive neuromodulation, addressing a clinical need to develop more minimally invasive approaches that are safer, more tolerable and versatile. In combination with a cavitation agent, the effects of ultrasound can be amplified and localized for therapy. Using c-Fos expression mapping, we show how ultrasound-sensitive nanodroplets can be used to induce either neurosuppression or neurostimulation, without disrupting the blood-brain barrier in rats. By repurposing a commercial ultrasound contrast agent, Definity, lipid-shell decafluorobutane-core nanodroplets of 212.5 ± 2.0 nm were fabricated and loaded with or without pentobarbital. FUS was delivered with an atlas-based targeting system at 1.66 MHz to the motor cortex of rats, using a feedback-controller to detect successful nanodroplet vaporization and drug release. Neuromodulation was quantified through changes in sensorimotor function and c-Fos expression. Following FUS-triggered delivery, sham nanodroplets induced a 22.6 ± 21% increase in local c-Fos expression, whereas pentobarbital-loaded nanodroplets induced a 21.7 ± 13% decrease (n = 6). Nanodroplets, combined with FUS, offer an adaptable tool for neuromodulation, through local delivery of small molecule anesthetics or targeted mechanical effects.
Introduction
Purpose
Drug delivery WITHOUT BBB opening
Study Objective
To determine whether ultrasound-sensitive nanodroplets combined with focused ultrasound can produce localized neurostimulation or neurosuppression in rat motor cortex—via mechanical effects or targeted pentobarbital delivery—without disrupting the blood–brain barrier.
Animal model / Human subject
Sprague-Dawley rats (sex: male)
Disease model
Healthy
MRI or image guidance method
Atlas-based targeting system
Targeted brain region(s)
Motor Cortex
Cargo name and characteristics
pentobarbital loaded nanodroplets with lipid shell and liquid DFB core.
Route of administration
intravenous
Outcomes and Safety
Summary of Outcomes
Atlas-targeted FUS at 1.66 MHz with feedback-controlled vaporization of 212.5 nm lipid-shell decafluorobutane nanodroplets produced bidirectional neuromodulation without BBB disruption: sham (no drug) droplets + FUS increased local c-Fos (~+22.6%) indicating neurostimulation, while pentobarbital-loaded droplets + FUS decreased c-Fos (~−21.7%) indicating neurosuppression.
Duration of biological effect
24 h
Safety-related matter
The study reports neuromodulation achieved without disrupting the blood–brain barrier in rats. No adverse effects or safety concerns are reported.
Brain Region
Ultrasound Parameters
Ultrasound instrument
pre-clinical prototype system (prototype RK50, FUS Instruments Inc., Canada)
FUS Frequency
1.66 MHz
FUS Pressure
1.1, 1.74
FUS Mode
pulsed
Pulse duration
10 ms
Duration of a single FUS session
180 s
Focal Characteristics
diameter: 43 mm, focal length: 35 mm
Treatment frequency
single session
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search